BEYOND GENOMiX logo

BEYOND GENOMiX

Proprietary multi-omics platform delivering actionable insights for age-related disease diagnostics and therapeutics

4 employees · est. 2023 · Neuchatel, Switzerland

VS
Gero logo

Gero

AI-driven drug discovery company focused on therapies targeting age-related diseases

140 employees · est. 2018 · Palo Alto, United States

Gero is the older company (2023 vs 2018); Gero is the larger of the two.

Side-by-Side Comparison

BEYOND GENOMiX Gero
Founded
2023 2018 older
Headquarters
Neuchatel, Switzerland Palo Alto, United States
Employees
4 140 larger
Industry
AI, Biotechnology, Health Care AI, Biotechnology, Insurtech
Funding Stage
Unknown Series A
Total Funding
Not tracked yet $8.20M
Funding Rounds
1 3
Services
Genomics Pipeline Development, Telomere Analysis Technology, AI-powered Senescence Analysis, Multi-omics Data Generation, Machine Learning Insights, End-to-End Aging Hallmarks Analysis Developing drugs targeting aging, AI models for disease progression, Collaborative drug discovery with pharma companies
Target Customers
Pharmaceutical Companies, Biotechnology Researchers, Healthcare Providers, Diagnostics Companies, Longevity Researchers Pharmaceutical companies, Healthcare researchers, Investors interested in biotechnology, Aging and longevity research institutions
Taxonomy
Proprietary Multi-Omics, Age-Related Disease Diagnostics, Therapeutics, Swiss Deeptech Start-up, Aging Hallmarks Analysis, Drug Discovery, MedTech, HealthTech, Precision Medicine, Age-Associated Diseases, Diagnostics AI Drug Discovery, Age-related Diseases, Preclinical Stage, Disease Phenotypes, Real-world Human Data, Genetic Study, Novel Target Discovery, Chronic Diseases, Longevity Research, Marker Identification, Drug Development, MHealth, Digital Health, Biological Age
Website
beyondgenomix.com gero.ai
BEYOND GENOMiX logo

About BEYOND GENOMiX

BEYOND GENOMiX, founded in 2023, is a promising Swiss startup in the AI, Biotechnology, and Health Care industries. Located in Switzerland, this deeptech venture is carving a niche in the burgeoning field of age-related disease diagnostics and therapeutics. The company's compelling slogan, "Proprie...

Gero logo

About Gero

Gero, founded in 2018, is an AI-driven drug discovery company focused on therapies targeting age-related diseases. The company is headquartered in the United States and operates at the intersection of AI, Biotechnology, Insurtech, and Pharmaceutical industries. At its core, Gero aims to eliminate a...

We will tell you when either one moves

BounceWatch watches BEYOND GENOMiX and Gero for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at BEYOND GENOMiX and Gero — by email.

Frequently Asked Questions

BEYOND GENOMiX — Proprietary multi-omics platform delivering actionable insights for age-related disease diagnostics and therapeutics. Gero — AI-driven drug discovery company focused on therapies targeting age-related diseases. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
BEYOND GENOMiX has raised undisclosed funding while Gero has raised $8.20M.
BEYOND GENOMiX and Gero operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare BEYOND GENOMiX with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at BEYOND GENOMiX on 11 Mar 2026, and Gero on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy